Enantia will be attending the CPhI North America 2018

Enantia will be attending the CPhI North America 2018

News

Home > News > Enantia will be attending the CPhI North America 2018

EnantiawillbeattendingtheCPhINorthAmerica2018

Enantia will be attending the CPhI North America 2018

April 12th, 2018

We will be attending the CPhI North America being held from 24th to 26th of April 2018 at the Pennsylvania Convention Center in Philadelphia, USA.

We would be delighted to meet with you there and let you know more of Enantia!

You can contact us at info@enantia.com to arrange a meeting.

 

Enantia will be attending the CPhI Worlwide 2018

Enantia will be attending the CPhI Worlwide 2018

News

Home > News > Enantia will be attending the CPhI Worlwide 2018

EnantiawillbeattendingtheCPhIWorlwide2018

Enantia will be attending the CPhI Worlwide 2018

September 25th, 2018

Enantia will be attending the CPhI Worldwide being held from the 9th to 11th of October 2018 in Madrid, Spain.

Meet us in our booth 7H61 and learn more about some of our most demanded services:

 


You can contact us at info@enantia.com to arrange a meeting.

Enantia at BioSpain 2018

Enantia at BioSpain 2018

News

Home > News > Enantia at BioSpain 2018

biospain

Enantia at BioSpain 2018

August 27th, 2018

We will be exhibiting at BioSpain 2018, being held from 25th to 27th of September 2018 in Seville, Spain.

You will find us at the BioRegio Pavilion. We would be delighted to meet with you there and discuss how we can contribute to your projects.

Contact us at info@enantia.com to arrange a meeting.

Enantia presents its new Sports Team

Enantia presents its new Sports Team

News

Home > News > Enantia presents its new Sports Team

enantia-announces-its-cannabinoids-cocrystal-platform

Enantia presents its new Sports Team

June 29th, 2018

Organised and run by some of our most athletic employees, Enantia’s Sports Team will participate in different challenges such as running races and hiking activities, always wearing our new corporate sport T-shirt. This activity promotes our team building spirit and healthy lifestyle, and at the same time we spend a nice time together.

In the picture you can see the elite trail runner Núria Picas, who visited us during Enantia’s 15th birthday, wearing her Enantia’s Sports Team T-shirt.

Enantia celebrates its 15th anniversary

Enantia celebrates its 15th anniversary

News

Home > News > Enantia celebrates its 15th anniversary

Enantiacelebratesits15thanniversary

Enantia celebrates its 15th anniversary

June 15th, 2018

On the 7th of June 2018, Enantia’s founders and employees enjoyed together the celebration of the company’s 15th birthday. In one of the activities we carried out, we were joined by the world champion ultra-trail runner Núria Picas, who inspired and gave us further motivation to achieve our objectives. The day continued with a cooking contest in a fantastic location in El Penedès, where we enjoyed the views, the food and tasted some of the local wine.

We want to thank our customers from all over the globe who have helped us reach this very important milestone.

Enantia will be attending Chemspec Europe 2018

Enantia will be attending Chemspec Europe 2018

News

Home > News > Enantia will be attending Chemspec Europe 2018

EnantiawillbeattendingChemspecEurope2018

Enantia will be attending Chemspec Europe 2018

May 24th, 2018

We will be attending Chemspec Europe being held the 20th and 21th of June 2018 at the Koelnmesse in Cologne, Germany.
 
We would be delighted to meet with you there and let you know more about Enantia!
 
You can contact us at info@enantia.com to arrange a meeting.
 

Enantia has received AEMPS’ permission to carry out studies with narcotic and psychotropic substances

Enantia has received AEMPS’ permission to carry out studies with narcotic and psychotropic substances

News

Home > News > Enantia has received permission from AEMPS …

EnantiahasreceivedpermissionfromAEMPS

Enantia has received permission from AEMPS to carry out studies with narcotic and psychotropic substances

May 15th, 2018

Enantia has received permission from the Spanish Agency of Medicines and Medical Devices (AEMPS) to carry out a study with a narcotic substance from the Lists I to IV, included in the Single Convention on Narcotic Drugs, 1961.
 
Furthermore, Enantia has also obtained permission from the AEMPs to work with a psychotropic substance controlled under the Convention on Psychotropic Substances, 1971.
 
In order to comply with the corresponding legal requirements we have developed new standard operating procedures and adapted our facilities. This opens the door for new authorisations to apply our expertise in Medicinal Chemistry and Process Chemistry, as well as in Solid Form Development in new projects with narcotic and psychotropic substances.
 
If you are looking for a reliable chemistry CRO who is able to work with narcotic and psychotropic substances do not hesitate to contact us.
 

Barcelona Science Park’s 20th anniversary

Barcelona Science Park’s 20th anniversary

News

Home > News > Barcelona Science Park’s 20th anniversary

BarcelonaScienceParks20thanniversary

Barcelona Science Park’s 20th anniversary

Last December the Barcelona Science Park (PCB) celebrated its 20th anniversary with an institutional event at the Antoni Caparrós auditorium.

The event was chaired by Prof. Joan Elias (rector of the University of Barcelona) and talks were given by prominent members of the PCB community including our CEO Dr. Joan Feixas, who was invited to share with the audience Enantia’s example of success of entrepreneurial initiatives, being one of the first companies to set up in the Park.

Other speakers that joined the celebration were Ms. Maria Terrades (Director of the Barcelona Science Park), Dr. Meritxell Teixidó (Institute for Research in Biomedicine), Dr. Josep Samitier (Director of the Institute of Bioengineering of Catalonia) and Dr. Carlos R. Plata-Salamán, (CSO, CMO and Head of R&D of Esteve Pharmaceuticals).

Today the PCB has a surface area of 100,000 m2 and a community of 2,700 professionals. More than 100 public and private organizations come together in this space, equipped with a strong technological offering.

Photo: From left to right: Carlos R. Plata-Salamán, Joan Feixas, Meritxell Teixidó, Joan Elias, Joan Corominas, Maria Terrades and Josep Samitier (Author: David Acedo, Parc Científic de Barcelona)

Enantia at Synchrotron ALBA workshop

Enantia at Synchrotron ALBA workshop

News

Home > News > Enantia at Synchrotron ALBA workshop

1_enantias_cannabidol

Enantia at Synchrotron ALBA workshop

May 21st, 2015

Enantia takes active part in the workshop of synchrotron light applications for the pharmaceutical industry organised by ALBA (Cerdanyola del Vallès, Barcelona), sharing with the audience the experience in using synchrotron light for sensitive analysis of drug products.

Read the full article

Enantia’s cocrystallization technology endorsed by global partnership

Enantia’s cocrystallization technology endorsed by global partnership

News

Home > News > Enantia’s cocrystallization technology endorsed by global partnership

Enantiascocrystallizationtechnologyendorsedbyglobalpartnership

Enantia’s cocrystallization technology endorsed by global partnership

« An innovative cocrystal obtained by Enantia is part of the partnership recently announced by Esteve and Mundipharma-Purdue »

March 9th, 2015

An innovative cocrystal, obtained by Enantia working in collaboration with Esteve R&D, is part of the global partnership recently announced by Esteve and Mundipharma-Purdue.

Enantia, a technology based company in the fields of medicinal chemistry, process chemistry and solid forms development, has played a fundamental role in one of the projects included in this partnership: obtaining a single new cocrystal entity composed of two active substances used in pain management.

Esteve designed a series of new therapeutic entity concepts based on different pairs of active substances, and started with Enantia an ambitious project to obtain salts and cocrystals from them. One of the outcomes of this project is E-58425, for which a new entity cocrystal patent was granted in Europe in 2013 and in the USA in 2014, that will rapidly move to Phase III clinical trials thanks to the global partnership of Esteve and Mundipharma-Purdue.

This development comes at an opportune moment when both FDA and EMA have recently given their guidance on the regulatory aspects of pharmaceutical cocrystals, thus paving the way to a new generation of drugs based on the cocrystallization concept.

The agreement between Esteve and Mundipharma-Purdue covers some additional assets that range from preclinical to clinical development and can represent payments to Esteve exceeding $1bn if all development, regulatory and sales milestones are met across all projects.